Business
Directors Holdings
Directors Holdings.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n RNS Number : 4459V Allergy Therapeutics PLC 10 July 2009 \n \nFriday 10 July 2009\n\n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or \"the Company\")\n\nDirectors Holdings \n\n\nAllergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that, further to an announcement dated 6 July 2009, the 12,500,000 ordinary shares issued to Azure Ventures Limited, pursuant to a partial exercise of a warrant on 2 July 2009 have been admitted to trading on AIM. \n\nAzure Ventures Limited is now interested in 116,666,666 shares, representing 42.19 per cent. of the Company's total voting rights.\n\nAlejandro Weinstein, a non-executive director of the Company, is one of the ultimate beneficiaries under The Karjiang Pharma Trust which is the sole shareholder of Azure Ventures Limited. \n\nThe Company's issued share capital consists of 276,498,551 ordinary shares. \n\n\n\nFor further information\n\n\n\n\n\nAllergy Therapeutics\n\n\n+44 (0) 1903 845 820\n\n\n\n\nKeith Carter, Chief Executive\n\n\n\n\n\n\n\nwww.allergytherapeutics.com\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNomura Code Securities\n\n\n+44 (0) 207 776 1200\n\n\n\n\nJuliet Thompson/ Clare Terlouw\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFinancial Dynamics\n\n\n+44 (0) 207 831 3113\n\n\n\n\nBen Brewerton/ Susan Quigley\n\n\n\n\n\n\n\n\n\n\n\nThis information is provided by RNSThe company news service from the London Stock Exchange END MSCUUUBPMUPBPUB\n ","length":3807,"tagName":"div"}]